Jul 20, 2026 09:01AM
Jul 20, 2026 09:00AM
Jul 14, 2026 07:00AM
Jul 13, 2026 09:01AM
Jul 13, 2026 09:00AM
Jun 16, 2026 09:00AM
Jun 16, 2026 09:00AM Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044
Jun 2, 2026 09:00AM
Jun 2, 2026 09:00AM
Jun 1, 2026 09:03AM
Jun 1, 2026 09:00AM
May 26, 2026 06:59AM
May 22, 2026 09:00AM
May 14, 2026 10:55AM "Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies
May 14, 2026 10:55AM
May 4, 2026 09:00AM
Apr 27, 2026 08:10AM
Apr 27, 2026 08:10AM
Apr 10, 2026 06:49AM
Apr 6, 2026 09:00AM
Apr 6, 2026 09:00AM Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer
Apr 1, 2026 09:02AM
Apr 1, 2026 09:00AM
Mar 19, 2026 11:00AM
Mar 19, 2026 09:00AM
Mar 2, 2026 09:02AM
Mar 2, 2026 09:00AM
Feb 24, 2026 09:01AM Oncolytics shifts focus to anal, colorectal cancer studies
Feb 24, 2026 09:00AM
Feb 17, 2026 10:48AM
Feb 5, 2026 09:26AM
Feb 4, 2026 08:50AM
Feb 4, 2026 08:50AM
Jan 15, 2026 04:01PM
Jan 14, 2026 10:39AM The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era
Jan 14, 2026 09:00AM
Jan 12, 2026 10:14AM
Jan 12, 2026 09:01AM
Jan 12, 2026 09:00AM
Jan 9, 2026 09:02AM
Jan 9, 2026 09:00AM
Jan 8, 2026 12:08PM The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech
Jan 8, 2026 09:02AM
Jan 8, 2026 09:00AM
Jan 7, 2026 12:15PM
Jan 7, 2026 09:01AM
Jan 7, 2026 09:00AM
Dec 16, 2025 12:18PM
Dec 16, 2025 09:01AM Oncolytics reports 33% response rate in colorectal cancer study
Dec 16, 2025 09:00AM

326,227 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All